SOST and chronic kidney disease: As CKD progress, the consequences of increased serum sclerostin lead to deceased bone formation by inhibiting Wnt-induced signaling through binding to LRP5/6 [14,16] and increased osteoclastogenesis by inducing RANK-L synthesis [17].